Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;7(2):100122.
doi: 10.1016/j.rpth.2023.100122. Epub 2023 Mar 15.

SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms

Oscar Borsani  1   2 , Virginia V Ferretti  3 , Ilaria C Casetti  1 , Daniele Vanni  1 , Chiara Trotti  1 , Daniela Pietra  2 , Annalisa De Silvestri  3 , Luca Arcaini  1   2 , Elisa Rumi  1   2
Affiliations

SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms

Oscar Borsani et al. Res Pract Thromb Haemost. 2023 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic overview of the study design. The exposure period included the 30 days after each SARS-CoV-2 vaccination; the nonexposure period included the 6 months before the first vaccination and the period beyond 30 days after each dose till the last follow-up.
Figure 2
Figure 2
The risk of thrombosis varies according to vaccination exposure. The risk of thrombosis in the exposure period did not significantly differ from the risk of thrombosis in the nonexposure period.
See this image and copyright information in PMC

References

    1. Marchetti M., Vannucchi A.M., Griesshammer M., Harrison C., Koschmieder S., Gisslinger H., et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9 e301–e11. - PubMed
    1. Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–e745. - PMC - PubMed
    1. Barbui T., Iurlo A., Masciulli A., Carobbio A., Ghirardi A., Carioli G., et al. Second versus first wave of COVID-19 in patients with MPN. Leukemia. 2022;36:897–900. - PMC - PubMed
    1. Barbui T., Vannucchi A.M., Alvarez-Larran A., Iurlo A., Masciulli A., Carobbio A., et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35:485–493. - PMC - PubMed
    1. Barbui T., De Stefano V., Alvarez-Larran A., Iurlo A., Masciulli A., Carobbio A., et al. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021;11:21. - PMC - PubMed